ASAM Weekly for January 3, 2023
This Week in the ASAM Weekly
To borrow from a conceptualization about human behavior — a good way to predict future news is to look at past news. This week we present to you the most read news publications of 2022.
Well-recognized individuals — celebrities (Rolling Stone) and physicians alike (New Haven Register)— are hugely important for helping shift our understanding of addiction. Treatments that are considered game changers (LA Times; MSN) or changing the course of illness (MedPage) will equally gain our attention.
There is always space in the news cycle for the next emerging drug threat whether it’s a derivation of cannabis (NY Times), an animal tranquilizer (KHN), or one of the most commonly prescribed medications (UPI). In addition, a deeper appreciation for the human experience and drug use has taken hold in recent years (NY Times), helping shepherd greater acceptance towards the psychedelic medicine movement (NY Times).
Wishing the best to all our colleagues for 2023.
Thanks for reading,
Nicholas Athanasiou, MD, MBA, DFASAM
Editor in Chief with Co-Editors: Brandon Aden, MD, Debra R. Newman, PA-C, MSPAS, MPH, Jack Woodside, MD, John A. Fromson, MDMost Read News of 2022
On ‘Last Week Tonight,’ John Oliver Takes on the Nation’s Dumbest Drug Myth
Rolling Stone
High-dose drug treats fentanyl overdose, if you can get it
New Haven Register
MSN/Insider
The Next Big Addiction Treatment
The New York Times
What Is Delta-8, and Why Is It So Popular?
The New York Times
Can a monthly injection be the key to curbing addiction? These experts say yes
Los Angeles Times
They Call It ‘Tranq’ — And It’s Making Street Drugs Even More Dangerous
KHN
Medication for Drinking Addiction May Thwart Liver Disease
MedPage Today
The Most Important Question About Addiction
The New York Times
Gabapentin's link to fatal drug overdoses draws concern
UPI News
Leave a comment
Recent and Past Issues
ASAM Weekly for January 3, 2023
This Week in the ASAM Weekly
To borrow from a conceptualization about human behavior — a good way to predict future news is to look at past news. This week we present to you the most read news publications of 2022.
Well-recognized individuals — celebrities (Rolling Stone) and physicians alike (New Haven Register)— are hugely important for helping shift our understanding of addiction. Treatments that are considered game changers (LA Times; MSN) or changing the course of illness (MedPage) will equally gain our attention.
There is always space in the news cycle for the next emerging drug threat whether it’s a derivation of cannabis (NY Times), an animal tranquilizer (KHN), or one of the most commonly prescribed medications (UPI). In addition, a deeper appreciation for the human experience and drug use has taken hold in recent years (NY Times), helping shepherd greater acceptance towards the psychedelic medicine movement (NY Times).
Wishing the best to all our colleagues for 2023.
Thanks for reading,
Nicholas Athanasiou, MD, MBA, DFASAM
Editor in Chief with Co-Editors: Brandon Aden, MD, Debra R. Newman, PA-C, MSPAS, MPH, Jack Woodside, MD, John A. Fromson, MDMost Read News of 2022
On ‘Last Week Tonight,’ John Oliver Takes on the Nation’s Dumbest Drug Myth
Rolling Stone
High-dose drug treats fentanyl overdose, if you can get it
New Haven Register
MSN/Insider
The Next Big Addiction Treatment
The New York Times
What Is Delta-8, and Why Is It So Popular?
The New York Times
Can a monthly injection be the key to curbing addiction? These experts say yes
Los Angeles Times
They Call It ‘Tranq’ — And It’s Making Street Drugs Even More Dangerous
KHN
Medication for Drinking Addiction May Thwart Liver Disease
MedPage Today
The Most Important Question About Addiction
The New York Times
Gabapentin's link to fatal drug overdoses draws concern
UPI News
This Week in Addiction Medicine Podcast
A weekly audio summary and podcast of the ASAM Weekly
The ASAM Weekly
Editors & Staff
Editor-in-Chief: Nicholas Athanasiou, MD, MBA, DFASAM
Emeritus Editor: William Haning, MD, DFAPA, DFASAM
Publications Chair: Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors: Brandon
Aden, MD, Debra R. Newman, PA-C, MSPAS, MPH, Jack Woodside, MD, John A. Fromson, MD
Please direct customer service inquiries and comments to: ASAMWeekly@ASAM.org
The ASAM Weekly
Advertiser Services & Sales
Ad space is limited and available on a first-paid, first-published basis. To assure your ad will run in the specific issue you select, Insertion Orders must be signed by an authorized person in your organization and accepted by your customer service representative before taking the advertising units out of the active sales inventory. Payment must be received prior to the run date for an ad. Insertion Orders provide several options for payment in full including all major credit cards or check. Pre-approved billing must be arranged directly by an ASAM representative.
To learn more about advertising opportunities
Contact: Bob Davis at Bdavis@ASAM.org